Skip to main content
Erschienen in: Clinical and Translational Oncology 3/2017

Open Access 25.08.2016 | Research Article

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

verfasst von: J. Salvador, J. A. Urtasun, F. J. B. Duart, R. García-Campelo, R. G. Carbonero, P. Lianes, A. Llombart, D. I. Casado, J. M. Piera, M. M. Mateu, J. Puente, F. Rivera, C. A. Rodríguez, J. A. Virizuela, M. Martín, P. Garrido

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The Spanish Society of Medical Oncology (SEOM) has conducted a study on the access to oncologic drugs across the 17 Spanish Regions with the aim of identifying potential heterogeneities and making proposals for eliminating the barriers identified at the different levels.

Methods

An Expert Panel made up of medical oncologists designed a survey on certain indications approved for 11 drugs in the approach of breast cancer, melanoma, lung cancer, prostate cancer and support treatment. This survey was sent to 144 National Health System (NHS) hospitals.

Results

77 hospitals answered the survey. The information modules analysed were: scope of the Commission that establishes binding decisions related to drug access; conditions, stages and periods of drug application, approval and administration processes; barriers to accessing drugs.

Conclusions

The study shows variability in drug access. The SEOM makes proposals addressed to reducing the differences identified and homogenizing drug access conditions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Stewart BW, Wild CP, editors. World Cancer Report 2014. The International Agency for Research on Cancer (IARC). 2014. Stewart BW, Wild CP, editors. World Cancer Report 2014. The International Agency for Research on Cancer (IARC). 2014.
2.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed 14 Dec 2015. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://​globocan.​iarc.​fr. Accessed 14 Dec 2015.
3.
Zurück zum Zitat Galcerán J, Ameijide A, Carulla M, Mateos A, Quirós JR, Alemán A, et al. Estimaciones de la incidencia y la supervivencia del cáncer en España y su situación en Europa. Red Española de Registros de Cáncer (REDECAN), 2014. Galcerán J, Ameijide A, Carulla M, Mateos A, Quirós JR, Alemán A, et al. Estimaciones de la incidencia y la supervivencia del cáncer en España y su situación en Europa. Red Española de Registros de Cáncer (REDECAN), 2014.
4.
Zurück zum Zitat Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, et al. Clinical cancer advances 2015: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol. 2015;33(7):786–809.CrossRefPubMed Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, et al. Clinical cancer advances 2015: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol. 2015;33(7):786–809.CrossRefPubMed
8.
Zurück zum Zitat IMS Institute for Healthcare Informatics. Developments in cancer treatments, market dynamics, patient access and value. Global Oncolog Trend Report 2015. 2015. IMS Institute for Healthcare Informatics. Developments in cancer treatments, market dynamics, patient access and value. Global Oncolog Trend Report 2015. 2015.
12.
Zurück zum Zitat Bergmann L, Enzmann H, Thirstrup S, Schweim JK, Widera I, Zwierzina H. Access to innovative oncology medicines in Europe. Ann Oncol. 2016;27(2):353–6.CrossRefPubMed Bergmann L, Enzmann H, Thirstrup S, Schweim JK, Widera I, Zwierzina H. Access to innovative oncology medicines in Europe. Ann Oncol. 2016;27(2):353–6.CrossRefPubMed
13.
Zurück zum Zitat Puigventós Latorre F, Santos-Ramos B, Ortega Eslava A, Durán-García ME; Grupo de Evaluación de Novedades, Estandarización e Investigación en Selección de Medicamentos (GENESIS) de la Sociedad Española de Farmacia Hospitalaria (SEFH). Variabilidad en la actividad y los resultados de la evaluación de nuevos medicamentos por las comisiones de farmacia y terapéutica de los hospitales en España. Farm Hosp. 2011;35(6):305–14. Puigventós Latorre F, Santos-Ramos B, Ortega Eslava A, Durán-García ME; Grupo de Evaluación de Novedades, Estandarización e Investigación en Selección de Medicamentos (GENESIS) de la Sociedad Española de Farmacia Hospitalaria (SEFH). Variabilidad en la actividad y los resultados de la evaluación de nuevos medicamentos por las comisiones de farmacia y terapéutica de los hospitales en España. Farm Hosp. 2011;35(6):305–14.
14.
Zurück zum Zitat Panteli D, Eckhardt H, Nolting A, Busse R, Kulig M. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries. Health Res Policy Syst. 2015;2015(13):39.CrossRef Panteli D, Eckhardt H, Nolting A, Busse R, Kulig M. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries. Health Res Policy Syst. 2015;2015(13):39.CrossRef
15.
Zurück zum Zitat Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71.CrossRefPubMed Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71.CrossRefPubMed
Metadaten
Titel
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions
verfasst von
J. Salvador
J. A. Urtasun
F. J. B. Duart
R. García-Campelo
R. G. Carbonero
P. Lianes
A. Llombart
D. I. Casado
J. M. Piera
M. M. Mateu
J. Puente
F. Rivera
C. A. Rodríguez
J. A. Virizuela
M. Martín
P. Garrido
Publikationsdatum
25.08.2016
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 3/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1535-8

Weitere Artikel der Ausgabe 3/2017

Clinical and Translational Oncology 3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.